News & Updates

Show Multimedia Only

Platinum-resistant ovarian cancer gets survival boost with add-on relacorilant

01 Jul 2025 by

Adding the first-in-class selective glucocorticoid receptor antagonist relacorilant to nab-paclitaxel results in improved survival outcomes for patients with platinum-resistant ovarian cancer, as shown in the topline results of the phase III ROSELLA study.

Platinum-resistant ovarian cancer gets survival boost with add-on relacorilant

01 Jul 2025

Add-on olanzapine prevents RT-induced nausea, vomiting

01 Jul 2025 by

In patients undergoing abdominal-pelvic radiation therapy (RT), treatment with olanzapine along with an antiemetic medication leads to a substantial decrease in RT-induced nausea and vomiting (RINV), with no serious adverse effects, reports a study presented at ASCO 2025.

Add-on olanzapine prevents RT-induced nausea, vomiting

01 Jul 2025

Surgery helps allay fear, worry in patients with thyroid cancer

01 Jul 2025

Fear and worry significantly decrease among patients with low-risk thyroid cancer (TC) following surgery, reports a recent study.

Surgery helps allay fear, worry in patients with thyroid cancer

01 Jul 2025

Aumolertinib shows promise in untreated EGFR-variant metastatic NSCLC

01 Jul 2025

High-dose aumolertinib appears to provide progression-free survival (PFS) benefit to patients with untreated EGFR-variant non–small cell lung cancer (NSCLC) and brain metastases, while having a manageable safety profile, according to the results of a single-arm phase II study.

Aumolertinib shows promise in untreated EGFR-variant metastatic NSCLC

01 Jul 2025

Adjuvant pertuzumab delivers survival gain in HER2+ EBC

01 Jul 2025 by

The APHINITY trial of adding pertuzumab to adjuvant therapy for early HER2+ breast cancer turns in a significant OS improvement, with results presented at ESMO Breast Cancer 2025 concluding a phase III trial spanning over a decade

Adjuvant pertuzumab delivers survival gain in HER2+ EBC

01 Jul 2025

ICIs improve survival in advanced MCC at population level

30 Jun 2025

Treatment of immune checkpoint inhibitors (ICIs) has led to a more than twofold increase in survival for patients with advanced Merkel cell carcinoma (MCC) at the population level, translating to about 220 fewer deaths annually in the US, according to a study.

ICIs improve survival in advanced MCC at population level

30 Jun 2025

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025 by

The oral, irreversible, HER2-selective tyrosine kinase inhibitor (TKI) zongertinib confers clinically meaningful benefit to patients with previously treated HER2-mutant nonsmall cell lung cancer (NSCLC), including those with brain metastases, while having a manageable safety profile, according to the phase 1A/1B Beamion LUNG-1 trial.

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

28 Jun 2025 by

For women with gynaecologic cancer undergoing inpatient palliative care in Singapore, music therapy helps create a comfortable space to disengage from difficult realities, celebrate life, and process grief and other challenging emotions, as shown in a qualitative study.

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

28 Jun 2025

TDABC may improve resource use in cancer care

27 Jun 2025 by

A study done in a single institution in Singapore has demonstrated the feasibility and practical application of time-driven activity-based costing (TDABC) in measuring the financial burden of chemotherapy regimens within an ambulatory oncology setting.

TDABC may improve resource use in cancer care

27 Jun 2025

Is anal cancer screening in MSM with HIV worth the buck?

26 Jun 2025

Screening for anal cancer among men who have sex with men (MSM) with HIV aged ≥35 years is cost-effective, according to a recent study. However, there is a need for value-based prioritization strategies to improve screening use.

Is anal cancer screening in MSM with HIV worth the buck?

26 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Platinum-resistant ovarian cancer gets survival boost with add-on relacorilant

Platinum-resistant ovarian cancer gets survival boost with add-on relacorilant

Add-on olanzapine prevents RT-induced nausea, vomiting

Add-on olanzapine prevents RT-induced nausea, vomiting

Surgery helps allay fear, worry in patients with thyroid cancer

Surgery helps allay fear, worry in patients with thyroid cancer

Aumolertinib shows promise in untreated EGFR-variant metastatic NSCLC

Aumolertinib shows promise in untreated EGFR-variant metastatic NSCLC

Adjuvant pertuzumab delivers survival gain in HER2+ EBC

Adjuvant pertuzumab delivers survival gain in HER2+ EBC

ICIs improve survival in advanced MCC at population level

ICIs improve survival in advanced MCC at population level

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

TDABC may improve resource use in cancer care

TDABC may improve resource use in cancer care

Is anal cancer screening in MSM with HIV worth the buck?

Is anal cancer screening in MSM with HIV worth the buck?